Baxter International, Inc. has entered into a definitive agreement to acquire Baxa Corp., a privately held company based in Englewood, CO, with additional operations in FL and the UK, for $380 million in cash. Baxa develops pharmacy technology to enhance the efficiency and safety of oral and IV dose preparation and delivery.

Among Baxa’s offerings are the ExactaMix Compounder, devices that automate multi-ingredient nutritional solution compounding and the DoseEdge Pharmacy Workflow Manager, an integrated system for managing IV and oral dose preparation activities. In 2010 Baxa had annual sales of approximately $150 million.

“With these new offerings, Baxter will be able to provide a comprehensive solution to fulfill the majority of patients’ nutritional requirements and increase efficiency in the pharmacy,” said Robert M. Davis, president of Baxter’s Medical Products business. “Bringing this expertise together with Baxter’s commercial capabilities and global reach will enable us to continue to meet our customers’ evolving needs and extend our position in IV nutrition and fluid delivery.”

“With this agreement, Baxa will be able to play a greater role in delivering safe medication practices,” said Greg Baldwin, Baxa chairman and chief executive officer. “We are very pleased to find a partner that shares our commitment and sees the potential in our products, technology and people.”